Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAVI BOTLA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1366540544
CMS profile
152441
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$621.06

33 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $621.06 33

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAVI BOTLA

NPI 1366540544 · CMS profile ID 152441

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1366540544?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAVI BOTLA, NPI 1366540544, CMS profile ID 152441. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1366540544?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RAVI BOTLA, NPI 1366540544, CMS profile ID 152441. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1366540544?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RAVI BOTLA, NPI 1366540544, CMS profile ID 152441, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1366540544?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

33 matching records · $621.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 33 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–33 of 33.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $20.3112/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886662599 CMS
ABBVIE INC. $8.8812/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640133 CMS
ABBVIE INC. $12.7412/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640131 CMS
GENZYME CORPORATION $152.1211/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938856673 CMS
ABBVIE INC. $22.4311/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640129 CMS
RedHill Biopharma Inc. $15.7010/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902973563 CMS
GENZYME CORPORATION $8.6510/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938856659 CMS
ABBVIE INC. $19.4810/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640127 CMS
ABBVIE INC. $16.4709/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640125 CMS
GENZYME CORPORATION $20.2509/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938856647 CMS
ABBVIE INC. $15.4409/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640123 CMS
ABBVIE INC. $17.3207/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640121 CMS
INTERCEPT PHARMACEUTICALS, INC. $12.5707/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951534307 CMS
ABBVIE INC. $13.5407/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640119 CMS
INTERCEPT PHARMACEUTICALS, INC. $12.4506/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951534305 CMS
ABBVIE INC. $21.5305/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640117 CMS
ABBVIE INC. $9.2705/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640115 CMS
ABBVIE INC. $15.1605/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640113 CMS
ABBVIE INC. $3.7705/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640111 CMS
INTERCEPT PHARMACEUTICALS, INC. $13.4005/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951534303 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.8505/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955597827 CMS
ABBVIE INC. $18.1704/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640109 CMS
ABBVIE INC. $12.5504/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640107 CMS
ABBVIE INC. $10.3004/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640105 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.4904/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960028419 CMS
ABBVIE INC. $18.3203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640103 CMS
ABBVIE INC. $11.1303/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640101 CMS
ABBVIE INC. $17.3203/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640099 CMS
ABBVIE INC. $16.6302/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640097 CMS
ABBVIE INC. $13.0902/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640095 CMS
ABBVIE INC. $14.8501/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640093 CMS
ABBVIE INC. $16.1301/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890640091 CMS
INTERCEPT PHARMACEUTICALS, INC. $11.7501/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951534301 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $537.95 14
PY2020 $60.65 4
PY2021 $484.39 25
PY2022 $621.06 33
PY2023 $817.01 36
PY2024 $142.18 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $5,156.00 5
PY2020 Principal investigator $12,353.90 32
PY2019 Principal investigator $30,348.97 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $7,014.92 12/31/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH PLLC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670120759
Principal investigator 1 Allergan Inc. $700.00 12/19/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670116737
Principal investigator 1 Allergan Inc. $86.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670113431
Principal investigator 1 Allergan Inc. $315.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670114079
Principal investigator 1 Allergan Inc. $991.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670115331
Principal investigator 1 Allergan Inc. $700.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670115619
Principal investigator 1 Allergan Inc. $315.00 12/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670115935
Principal investigator 1 Allergan Inc. $1,529.50 12/11/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH PLLC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670108361
Principal investigator 1 Allergan Inc. $3,220.50 12/11/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH PLLC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670108521
Principal investigator 1 Allergan Inc. $630.00 12/10/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670107949
Principal investigator 1 Allergan Inc. $686.00 12/10/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670107975
Principal investigator 1 Allergan Inc. $991.00 12/03/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670105253
Principal investigator 1 Allergan Inc. $315.00 10/17/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670086547
Principal investigator 1 Allergan Inc. $3,029.55 10/09/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH PLLC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670083765
Principal investigator 1 Allergan Inc. $250.00 10/01/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH PLLC
46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure No dispute reported 06/30/2026 670081519
Principal investigator 1 Allergan Inc. $500.00 09/01/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH PLLC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670071197
Principal investigator 1 Allergan Inc. $5,225.00 08/23/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH PLLC
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670068499
Principal investigator 1 Allergan Inc. $250.00 08/19/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH PLLC
A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis No dispute reported 06/30/2026 670067185
Principal investigator 1 Allergan Inc. $3,600.50 01/03/2019 Non-covered Recipient Entity
PINNACLE CLINICAL RESEARCH
12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RELAMORELIN IN PATIENTS WITH DIABETIC GASTROPARESIS No dispute reported 06/30/2026 670014717

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2024 Amount invested $0.00 1
PY2024 Value of interest $25,816.06 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $25,816.06 1
PY2022 Amount invested $59.66 1
PY2022 Value of interest $1,621.54 1
PY2021 Amount invested $1,247.84 1
PY2021 Value of interest $1,560.22 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

4 records · PY2021–2024

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2024 GastroGPO, LLC $0.00 $25,816.06 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1124818352
PY2023 GastroGPO, LLC $0.00 $25,816.06 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 1050729669
PY2022 GastroGPO, LLC $59.66 $1,621.54 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 954999671
PY2021 GastroGPO, LLC $1,247.84 $1,560.22 Common Stock Physician Covered Recipient No dispute reported 06/30/2026 854914647